GNTA Genenta Science S.p.A.

Nasdaq genenta.com


$ 3.52 $ -0.53 (-13.25 %)    

Monday, 27-Oct-2025 11:31:29 EDT
QQQ $ 626.55 $ 0.00 (0 %)
DIA $ 474.55 $ -0.24 (-0.05 %)
SPY $ 683.50 $ 0.73 (0.11 %)
TLT $ 91.32 $ 0.01 (0.01 %)
GLD $ 367.14 $ -3.87 (-1.04 %)
$ 6.2
$ 4.00
$ 3.48 x 100
$ 3.52 x 734
$ 3.40 - $ 4.06
$ 2.56 - $ 10.00
21,595,070
na
113.4M
$ 0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 genenta-extends-collaboration-with-anemocyte-to-boost-off-the-shelf-genetic-therapy-production

Genenta Science shares jumped ~324% premarket to $13.69 after expanding its plasmid DNA collaboration with ANEMOCYTE.

Core News & Articles

INTC: 9% | Intel shares are trading higher after the company reported Q3 EPS and sales above expectations. COIN: 3% | Coinbase ...

 genenta-science-collaborates-with-anemocyte-for-manufacturing-critical-starting-materials-for-cutting-edge-cell-based-therapies

Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collabor...

 genenta-science-secures-219m-funding-via-mandatory-convertible-bond-from-enea-tech-to-advance-temferon-in-metastatic-renal-cell-cancer

Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 mill...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION